# CPS-Cancer Prevention & Survivorship Research Program

> **NIH NIH P30** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2020 · $58,420

## Abstract

Cancer Prevention and Survivorship – Project Summary
Cancer Prevention and Survivorship (CPS) focuses on pre-cancerous biology and its translation into initial
testing of new prevention strategies, as well as interventions aimed at improving the quality of life for cancer
survivors. In the Pre-Cancerous Biology and Risk Biomarkers theme, research centers on tissue changes that
serve as indicators or predictors of malignant transformation and potential targets for developing new
preventive strategies. In the Prevention and Survivorship Translational Research theme, basic scientists from
the Pre-Cancerous Biology and Risk Biomarkers theme work with behavioral and clinical researchers for early
testing of new strategies. CPS is unique from Cancer Control and Population Control (CCPH) in that CPS
focuses on the discovery of new biomarkers and early phase testing of prevention and survivorship
interventions using high-risk individuals, whereas CCPH focuses on implementation of known effective
strategies. CPS has 21 full and 10 associate members from 16 departments/divisions with expertise in cancer
biology, medical and surgical oncology, radiation biology, gastroenterology, nursing, clinical health psychology,
nutrition, exercise physiology and biomedical informatics. In 2015, CPS increased the number of NCI (12) and
total peer-reviewed (29) funded grants from 6 and 24 since 2011, the previous CCSG submission. Seven of
the peer-reviewed grants are multi-PI awards, up from one. NCI and total peer-reviewed funding increased
from $1,804,303 and $6,244,484 to $3,098,479 and $11,890,377. From 2012-2015, over 800 patients were
accrued to 15 intervention trials. Twelve of these trials were investigator-initiated and three peer-reviewed
funded. Kansas and Missouri have high rates of adult obesity. Thus, many of the CPS interventional trials
focus on physical activity and weight reduction, in close collaboration with catchment area partners. CPS
members have published 382 articles since 2012 of which 164 (43%) had intra-programmatic, 127 (33%) had
inter-programmatic and 204 (54%) had inter-institutional collaborations. Forty-five publications (12%) had a
journal impact factor ≥ 8. CPS contributes to KUCC with significant leadership (Director and three ADs, Chair
PRMC, Co-chair SWOG Survivorship Committee) and highly translational biomarker based early phase
prevention and survivorship trials often with parallel animal studies. The SWOG chair position helps move
promising pilots into larger co-operative group trials. KUCC contributes to CPS both through shared resources
and pilot funding. In the future, CPS will continue to build on its strengths of novel pre-cancerous models, new
risk and response biomarkers, high-risk cohorts for early phase trials, energy balance and natural products in
chemoprevention trials. CPS will increase collaborations with CB to expand biomarker research in
metabolomics, with D3ET to develop natural product analogues for primary prev...

## Key facts

- **NIH application ID:** 9975744
- **Project number:** 5P30CA168524-09
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** Dan Alan Dixon
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $58,420
- **Award type:** 5
- **Project period:** 2012-07-11 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9975744

## Citation

> US National Institutes of Health, RePORTER application 9975744, CPS-Cancer Prevention & Survivorship Research Program (5P30CA168524-09). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9975744. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*